CME

CME Group

$319.37

+0.44%
Nov 16, 2026
Bobby Quantitative Model
CME Group Inc. operates the world's largest and most diversified derivatives marketplace, providing futures and options trading and clearing across interest rates, equity indexes, foreign currencies, energy, metals, and agricultural commodities, while also generating recurring revenue from market data and a 27% stake in S&P Dow Jones Indices. The company is the dominant platform in global risk management, functioning as a near-monopoly clearinghouse whose network effects, deep liquidity pools, and exclusive S&P futures franchise make it structurally distinct from both traditional exchanges and newer electronic entrants. The current investor narrative centers on record trading volumes and margin expansion, with Q3 2026 revenue up 12.99% year-over-year to $1.74 billion and net income of $1.04 billion, while a hawkish Federal Reserve under Chair Kevin Warsh and a renewed rate-hiking cycle are simultaneously fueling volatility-driven volume growth and pressuring richly valued equities. Analysts have taken notice, with JP Morgan upgrading the stock to Overweight in late October 2026, and the debate now hinges on whether elevated volatility and rate uncertainty can sustain the volume tailwind or whether peak activity is already priced in.

People also watch

S&P Global

S&P Global

SPGI

Analysis
Intercontinental Exchange

Intercontinental Exchange

ICE

Analysis
Moody's Corporation

Moody's Corporation

MCO

Analysis
Nasdaq, Inc.

Nasdaq, Inc.

NDAQ

Analysis
MSCI

MSCI

MSCI

Analysis

BobbyInvestment Opinion: Should I buy CME Today?

Rating: Hold. CME is a structurally elite business — a 62.02% net margin, 86.09% gross margin, $4.333 billion of trailing free cash flow, and a 0.119 debt-to-equity ratio — but at $317.97 the stock trades essentially at the 16-analyst consensus target of $317.06, implying ~0% upside, which caps the risk/reward despite the Buy consensus (recommendation mean 2.41; 9 Buy, 6 Hold, 2 Sell). The core thesis is that CME is a high-quality, volume-leveraged toll booth on global risk management whose current earnings power is already fully reflected in the price, so investors are being paid a 4.0% dividend yield to wait for either estimate revisions or a better entry point.

The supporting evidence is genuinely strong on quality but neutral on price. Revenue grew 12.99% year-over-year to $1.737 billion in Q3 2026, net income rose 14.2% to $1.037 billion, and trailing FCF of $4.333 billion yields roughly 4.4% against the ~$98.2 billion market cap, funding a 4.0% dividend and $520.4 million of quarterly buybacks. However, the trailing PE of 24.43x versus forward PE of 24.01x implies the market expects essentially flat earnings growth (forward EPS $16.90 vs. trailing ~$13.01), the PEG of 1.59 is only fair, and the 15.06x PS and 16.83x EV/EBITDA are rich absolute multiples that depend on margins staying near 62%. Against the analyst range of $227.00 to $367.00, the current price sits almost exactly at the midpoint, confirming fair rather than discounted valuation.

The biggest risks that could invalidate even a Hold are: (1) a normalization of rate-hike-driven volatility that reverses the 12.99% revenue growth and compresses the multiple toward the $227 low target (-28.6%); (2) margin pressure given the 97.25% payout ratio leaves almost no retained-earnings buffer; and (3) a de-rating of the 24x multiple if the Fed pauses. This Hold would upgrade to Buy on a pullback toward the $270–$290 breakout zone (implying ~10–15% upside to consensus) or on upward EPS revisions that lift the forward PE gap, and would downgrade to Sell if revenue growth decelerates below ~5% or gross margin falls below 85%. Verdict: fairly valued relative to both its own 19.3x–32.8x historical PE band and the analyst consensus — not overvalued, but offering no margin of safety at current levels.

Sign up to view all

CME 12-Month Price Forecast

CME is a top-tier business trading at a fair price with no margin of safety: the 62% net margin, 4.4% FCF yield, and fortress balance sheet justify a premium multiple, but the 24x PE on essentially flat forward earnings and a consensus target identical to the current price leave little room for upside. The 12.99% revenue growth is real but is tied to a rate-hike-driven volatility regime that could prove cyclical, and the wide $227–$367 analyst range reflects genuine disagreement about whether that regime is structural. The JP Morgan upgrade and defensive rotation into low-beta names support sentiment, but the 6 Hold and 2 Sell ratings and the 97.25% payout ratio temper enthusiasm. I would upgrade to bullish on a pullback toward $270–$290 or on upward EPS revisions that widen the trailing-to-forward PE gap, and downgrade to bearish if revenue growth decelerates below 5% or volatility normalizes sharply.

Historical Price
Current Price $319.37
Average Target $315.00
High Target $367.00
Low Target $227.00

Wall Street consensus

Most Wall Street analysts maintain a constructive view on CME Group's 12-month outlook, with a consensus price target around $317.06 and implied upside of -0.7% versus the current price.

Average Target

$317.06

17 analysts

Implied Upside

-0.7%

vs. current price

Analyst Count

17

covering this stock

Price Range

$227 - $367

Analyst target range

Buy
9 (53%)
Hold
6 (35%)
Sell
2 (12%)

CME is covered by 16 analysts with a consensus recommendation of Buy and a recommendation mean of 2.41, distributed as 9 Buy, 6 Hold, and 2 Sell ratings, reflecting a moderately bullish but not unanimous view. The average target price of $317.06 is essentially identical to the current price of $317.97, implying roughly 0% upside to consensus, which signals that the stock has already rallied to fair value in the eyes of the analyst community and that further gains would require either estimate revisions or multiple expansion. The consensus leans cautiously bullish, with the majority of ratings in the Buy camp but a meaningful 37.5% Hold and 12.5% Sell contingent tempering enthusiasm. The full target range spans $227.00 to $367.00, a wide $140 spread that signals significant disagreement about the company's trajectory. The high target of $367.00, roughly 15.4% above the current price, likely assumes continued volume acceleration from rate-hike-driven volatility, further margin expansion, and multiple re-rating toward the upper end of the historical PE band, while the low target of $227.00, about 28.6% below current levels, prices in a normalization of trading volumes, margin compression, and a de-rating toward the low end of the historical range. The wide spread reflects genuine uncertainty about whether the current volatility regime is structural or cyclical. Institutional ratings show a notable pattern of stability with a positive tilt: JP Morgan upgraded to Overweight from Underweight on October 22, 2026, a meaningful signal of improving sentiment, while Wells Fargo, Piper Sandler, and Morgan Stanley maintained Overweight ratings and UBS and Barclays held Neutral and Equal Weight respectively. The absence of recent downgrades and the presence of an upgrade suggest analyst sentiment is stabilizing or improving, though the lack of target price increases accompanying the upgrade leaves the consensus average anchored near the current price.

Drowning in data?

Find the real signal!

Bulls vs Bears: CME Investment Factors

The bull case rests on hard, current numbers: 12.99% revenue growth, a 62.02% net margin, $4.333 billion of trailing free cash flow, a 0.119 debt-to-equity ratio, and an exclusive S&P futures franchise — a genuinely rare quality profile. The bear case is equally data-grounded but more forward-looking: consensus target upside is ~0%, the trailing-to-forward PE gap (24.43x vs 24.01x) implies flat earnings growth, and the entire volume tailwind is tied to a rate-hike-driven volatility regime that could normalize. On balance the evidence currently favors the bull side on business quality and momentum (JP Morgan upgrade, +13.60 one-month relative strength), but the bear side wins on valuation asymmetry — there is no margin of safety at $317.97 with a $227 low target. The single most important tension is whether elevated volatility is structural or cyclical: if rate-hike-driven volumes persist through 2027, estimates rise and the stock breaks above $329.16; if volatility mean-reverts, the 24x multiple on flat earnings compresses toward the $227–$290 zone.

Bullish

  • Volume-leveraged revenue re-acceleration: Q3 2026 revenue of $1.737 billion grew 12.99% year-over-year from $1.538 billion, an acceleration versus earlier 2025 quarters (Q1 2025 was $1.642 billion). With clearing and transaction fees at $1.378 billion (~79% of segment revenue) riding a largely fixed cost base, each incremental contract drops through at very high incremental margins.
  • Elite 62% net margin economics: Q3 2026 net income of $1.037 billion on $1.737 billion of revenue produced a 62.02% trailing net margin, with gross margin at 86.09% and operating margin at 64.86%. Net income rose 14.2% year-over-year from $908 million in Q3 2025, showing operating leverage as volumes scale.
  • Fortress balance sheet and 4.4% FCF yield: Debt-to-equity is just 0.119 and Q3 2026 free cash flow of $1.070 billion was generated against only $15.8 million of capex. Trailing FCF of $4.333 billion on a ~$98.2 billion market cap yields roughly 4.4%, funding a 4.0% dividend yield plus $520.4 million of quarterly buybacks.
  • Structural monopoly on S&P futures: CME's 27% stake in S&P Dow Jones Indices makes it the exclusive venue to trade and clear S&P futures contracts, a franchise no competitor can replicate. This network-effect moat underpins pricing power and the 15.06x PS ratio that the market is willing to pay for 62% net margins.

Bearish

  • Zero implied upside to consensus target: The average analyst target of $317.06 is essentially identical to the $317.97 current price, implying ~0% upside. With 6 Hold and 2 Sell ratings out of 16 (recommendation mean 2.41), the analyst community is signaling the stock has already rallied to fair value.
  • Flat earnings growth priced at 24x: Trailing PE of 24.43x versus forward PE of 24.01x implies the market expects essentially flat earnings growth over the next twelve months, despite the 12.99% revenue growth. Forward EPS of $16.90 against trailing EPS of ~$13.01 leaves little room for multiple expansion without estimate revisions.
  • Volume tailwind may be cyclical, not structural: The rally is driven by a hawkish Fed under Chair Kevin Warsh and a renewed rate-hiking cycle fueling volatility. If volatility normalizes, the volume leverage that produced 12.99% revenue growth reverses — the $227 low target (~28.6% below current) prices exactly this normalization scenario.
  • Technically overextended near 52-week high: At $317.97 the stock sits at ~90% of its $218.31–$329.16 range and just 3.4% below the 52-week high after a 45% run off the June 2026 low of $218.58. The -33.05% max drawdown shows how sharply sentiment can reverse from elevated levels.

CME Technical Analysis

CME is in a powerful, sustained uptrend, with the stock up 12.14% over the past year and 17.91% year-to-date, and the current price of $317.97 sits at approximately 90% of its 52-week range of $218.31 to $329.16. That positioning near the top of the annual range signals strong momentum but also raises the risk of overextension, particularly as the stock trades just 3.4% below its 52-week high. The recovery from the June 2026 trough near $218.58 has been remarkably linear, with the stock adding roughly $99 or 45% from that low, confirming a durable trend rather than a dead-cat bounce. Short-term momentum is accelerating sharply: the stock is up 11.34% over the past month and 17.85% over three months, dramatically outpacing the S&P 500's -2.26% and -2.83% respective returns, producing relative strength readings of +13.60 and +20.68 over those windows. This divergence from a weakening broad market is a classic sign of defensive rotation into high-quality, cash-generative compounders, though the 1-year relative strength of -0.13% versus SPY's +12.27% shows CME has only recently reclaimed market leadership after lagging for much of the year. The 6-month gain of 6.39% versus SPY's 2.13% confirms the acceleration is a recent phenomenon rather than a full-year trend. Key technical support sits at the 52-week low of $218.31, with intermediate support around the $290-295 breakout zone from late October; resistance is defined by the 52-week high of $329.16, and a clean breakout above that level would signal a fresh leg higher and likely trigger momentum-driven buying. A breakdown below $290 would suggest the recent rally is losing steam and could open a retest of the $270 area. The stock's beta of just 0.184 is a critical risk-management consideration, indicating CME moves with only about 18% of the market's volatility, making it a low-beta defensive holding that requires larger position sizing to achieve equivalent portfolio exposure and offering natural downside cushioning in a sell-off. The maximum drawdown of -33.05% over the period, however, shows the stock is not immune to sharp corrections when sentiment shifts.

Beta

0.18

0.18x market volatility

Max Drawdown

-33.0%

Largest decline past year

52-Week Range

$218-$329

Price range past year

Annual Return

+12.0%

Cumulative gain past year

PeriodCME ReturnS&P 500
1m+8.7%-3.0%
3m+17.6%-3.6%
6m+10.1%-0.2%
1y+12.0%+10.1%
ytd+18.4%+8.5%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

CME Fundamental Analysis

CME's revenue trajectory is robust and re-accelerating, with Q3 2026 revenue of $1.737 billion representing 12.99% year-over-year growth from $1.538 billion in Q3 2025, and the multi-quarter trend shows sequential strength from $1.706 billion in Q2 2026 and $1.880 billion in Q1 2026. The growth is driven overwhelmingly by clearing and transaction fees of $1.378 billion, which constitute roughly 79% of segment revenue, supplemented by market data at $243.1 million and other revenue at $116.1 million, reflecting the leverage of rising volumes against a largely fixed cost base. The year-over-year comparison is particularly telling: Q3 2026 revenue of $1.737 billion versus Q3 2025's $1.538 billion marks a clear acceleration from the more modest growth seen earlier in the cycle, and the consensus 2026 revenue estimate of $8.865 billion implies continued momentum. This growth profile supports the investment case as a volume-leveraged, high-margin toll booth on global risk management. Profitability is exceptional, with Q3 2026 net income of $1.037 billion and a net margin of 62.02%, while gross margin stands at 86.09% and operating margin at 64.86%, placing CME among the most profitable businesses in financial services. The quarterly progression shows net income of $1.037 billion in Q3 2026 versus $908 million in Q3 2025, a 14.2% increase, and the net margin has expanded from 59.05% in the year-ago quarter to 59.68% on a reported basis, with the trailing net margin of 62.02% reflecting the benefit of operating leverage. Gross margin has been remarkably stable in the 85-94% range across recent quarters, underscoring the scalability of the exchange model where incremental volume carries minimal incremental cost. The balance sheet is fortress-like, with a debt-to-equity ratio of just 0.119 and a current ratio of 1.032, while trailing free cash flow of $4.333 billion against a market cap of roughly $98.2 billion yields an FCF yield of about 4.4%. Q3 2026 free cash flow of $1.070 billion was generated from operating cash flow of $1.086 billion against capital expenditure of just $15.8 million, demonstrating the asset-light nature of the business, and the company returned capital aggressively through $464.8 million in dividends and $520.4 million in buybacks during the quarter. ROE of 14.08% and ROA of 1.52% reflect the capital-intensive nature of the balance sheet due to clearinghouse margin deposits, but the underlying economics are highly cash-generative, with the dividend payout ratio of 97.25% signaling a commitment to returning nearly all earnings to shareholders while still funding growth internally.

Quarterly Revenue

$1.7B

2026-09

Revenue YoY Growth

+13.0%

YoY Comparison

Gross Margin

94.0%

Latest Quarter

Free Cash Flow

$4.3B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

MarketData
OtherRevenue
clearing and transaction fees

Open an Account, get $2 TSLA now!

Valuation Analysis: Is CME Overvalued?

Because CME is solidly profitable with trailing net income of $1.037 billion in Q3 2026 alone, the PE ratio is the appropriate primary metric, and the stock trades at a trailing PE of 24.43x against a forward PE of 24.01x, a remarkably narrow gap that implies the market expects essentially flat earnings growth over the next twelve months. That compressed trailing-to-forward spread is unusual for a high-quality compounder and suggests either that consensus estimates are conservative or that the market is already pricing in a plateau in earnings, with the forward PE of 24.01x based on estimated EPS of $16.90 against trailing EPS of roughly $13.01. The PEG ratio of 1.59 indicates the stock is reasonably valued relative to its growth rate, neither cheap nor egregiously expensive. Against the broader financial data and stock exchange industry, CME's PE of 24.43x represents a moderate premium, though the more striking comparison is the price-to-sales ratio of 15.06x and EV/EBITDA of 16.83x, which reflect the market's willingness to pay up for the company's 62% net margin and 86% gross margin. The PS ratio of 15.06x is elevated in absolute terms but is justified by margins that are roughly double the typical exchange operator, and the EV/Sales of 16.58x versus the EV/EBITDA of 16.83x shows the enterprise value is almost entirely equity-funded given the minimal net debt. The price-to-book ratio of 3.42x is modest for a company with 14.08% ROE, and the price-to-cash-flow of 22.96x is reasonable for a business generating $4.33 billion in trailing free cash flow. Historically, CME's PE ratio has ranged from roughly 19.3x to 32.8x over the past several years, with the current 24.43x sitting near the middle of that band and well below the 2021 peak of 32.82x and the 2025 Q3 reading of 27.13x. The PS ratio of 15.06x, however, is near the low end of its historical range of roughly 45x to 71x on a quarterly basis, though the discrepancy reflects differing share counts and revenue bases across periods. The current valuation is neither stretched nor deeply discounted relative to CME's own history, suggesting the market is pricing in steady, modest growth rather than euphoria, and the 4.0% dividend yield provides a meaningful income cushion that supports the valuation floor.

PE

24.4x

Latest Quarter

vs. Historical

Mid-Range

5-Year PE Range 19x~28x

vs. Industry Avg

32.4x

Industry PE ~32.4x*

EV/EBITDA

16.8x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on the concentration of revenue in transaction fees — $1.378 billion of the $1.737 billion Q3 2026 total (~79%) — which makes earnings highly sensitive to contract volumes rather than recurring subscriptions. The 97.25% dividend payout ratio leaves minimal retained-earnings buffer, and the 4.0% dividend yield is only sustainable if the $4.333 billion trailing FCF holds; a volume downturn would pressure both coverage and the buyback ($520.4 million in Q3). Earnings volatility is real: quarterly net income has ranged from $874.6 million (Q4 2024) to $1.168 billion (Q4 2025), and the Q3 2026 gross margin of 94.0% versus Q2 2026's 69.2% shows how clearing-related cost timing can swing reported margins quarter to quarter. Market and competitive risks are dominated by valuation compression: at 24.43x trailing PE, 15.06x PS, and 16.83x EV/EBITDA, CME trades at a premium that depends on margins staying near 62%, and the forward PE of 24.01x implies the market already assumes flat growth. The macro backdrop is a double-edged sword — a hawkish Fed under Chair Kevin Warsh and a near-certain December 2026 rate hike (with a reported 35% chance of at least four hikes by September 2027) fuel the volatility that drives volumes but also threaten richly valued equities broadly; CME's beta of just 0.184 cushions market sell-offs but does not protect against a de-rating of its own multiple. Peer results (CBOE and Intercontinental Exchange both beat on Q3 volumes) confirm the sector tailwind, but Zacks' caution that CBOE's growth 'may be hard to sustain as market volatility normalizes' applies equally to CME. The worst-case scenario is a rapid normalization of volatility combined with a Fed pause: volumes fall, the 12.99% revenue growth reverses, estimates are cut, and the multiple compresses from 24.4x toward the low end of its 19.3x–32.8x historical band. That path would take the stock toward the analyst low target of $227.00, roughly -28.6% from $317.97, and a retest of the 52-week low of $218.31 would imply about -31.3%; the -33.05% max drawdown on record shows losses of this magnitude are historically plausible, not theoretical.

FAQ

Ranked by severity: first, cyclical volume risk — clearing and transaction fees are about 79% of revenue ($1.378 billion of $1.737 billion in Q3 2026), so a normalization of rate-hike-driven volatility would reverse the 12.99% growth and is the path to the $227.00 low target, roughly -28.6%. Second, valuation compression — at 24.43x trailing PE, 15.06x sales, and 16.83x EV/EBITDA, the multiple depends on margins holding near 62%, and a Fed pause could de-rate the stock toward the low end of its 19.3x–32.8x historical band. Third, payout and margin risk — the 97.25% dividend payout ratio leaves almost no retained-earnings buffer, and quarterly gross margin has swung from 69.2% (Q2 2026) to 94.0% (Q3 2026) on clearing-cost timing. Fourth, macro and sentiment risk — a hawkish Fed under Chair Kevin Warsh and a near-certain December 2026 hike threaten richly valued equities broadly; CME's 0.184 beta cushions market sell-offs but not a de-rating of its own multiple, and the -33.05% max drawdown shows sharp corrections are historically plausible.

The scenario framework assigns a 55% probability to the base case of $300–$330, a 25% probability to the bear case of $227–$270, and a 20% probability to the bull case of $345–$367. The base case is most likely: volumes stay healthy but decelerate from 12.99% growth as the rate cycle matures, net margin holds near 62%, forward EPS tracks the $16.90 consensus, and the stock trades around the $317.06 average target with the 52-week high of $329.16 as resistance. The bull case requires a confirmed December 2026 hike plus further hikes into 2027, low-to-mid-teens revenue growth, and a re-rating toward the $367.00 high target (~15.4% upside). The bear case assumes rapid volatility normalization and a Fed pause, compressing the multiple toward the $227.00 low target (-28.6%) and risking the $218.31 52-week low. The key assumption across all three is whether elevated volatility is structural or cyclical.

CME looks fairly valued rather than cheap or stretched. The trailing PE of 24.43x sits near the middle of its historical 19.3x–32.8x band and well below the 2021 peak of 32.82x, while the forward PE of 24.01x on $16.90 consensus EPS shows the market is not pricing in meaningful earnings growth. The richer absolute multiples — 15.06x sales, 16.83x EV/EBITDA, and 22.96x price-to-cash-flow — are defensible given a 62.02% net margin roughly double that of a typical exchange operator, and the 1.59 PEG and 3.42x price-to-book against a 14.08% ROE are unremarkable rather than alarming. The clearest valuation signal is the analyst range: the current price sits almost exactly at the midpoint of $227.00 to $367.00 and at the $317.06 average. What the market is paying for is durability — steady volumes, a 4.0% yield, and a fortress balance sheet — not acceleration, which caps near-term re-rating potential.

From a pure risk/reward standpoint the setup is balanced rather than compelling: at $317.97 the stock sits essentially at the 16-analyst average target of $317.06, implying roughly 0% upside, even though the consensus rating is Buy (9 Buy, 6 Hold, 2 Sell; mean 2.41). The quality case is strong — 12.99% year-over-year revenue growth, a 62.02% net margin, $4.333 billion of trailing free cash flow, and a 4.0% dividend yield — but the trailing-to-forward PE gap of 24.43x versus 24.01x implies flat forward earnings, so multiple expansion requires estimate revisions rather than simply time. The biggest downside risk is volatility mean-reversion, which the $227.00 low target (-28.6%) and the $218.31 52-week low (-31.3%) quantify. It is a good buy for income-oriented, low-volatility-tolerant investors with a multi-year horizon, and a better buy on a pullback into the $270–$290 zone where implied upside to consensus widens to roughly 10–15%.

CME is structurally a long-term holding, not a trading vehicle. Its 0.184 beta means it moves with only about 18% of the market's volatility, so short-term price swings are muted and momentum trades offer limited payoff, while the 4.0% dividend yield and $520.4 million of quarterly buybacks reward patience. Earnings visibility is high — gross margin has held in the 85–94% range across recent quarters and net income has grown from $874.6 million in Q4 2024 to $1.168 billion in Q4 2025 — but the 97.25% payout ratio means total return depends on the share price, which is tied to the volatility cycle. The stock's 45% run off the June 2026 low of $218.58 and its position 3.4% below the 52-week high argue against chasing it short-term. A minimum holding period of two to three years is appropriate, sized larger than a typical position given the low beta, and best accumulated on pullbacks toward $270–$290.